Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas.
RAP-5, a monoclonal antibody raised against a p21ras peptide, has been claimed to show immunohistochemical localisation of cells with infiltrative properties in human tumours. We confirmed that this antibody reveals pronounced cellular heterogeneity in human colonic neoplasms but could find no obvious relationship to infiltrative activity. RAP-5 bound to many different cell types, neoplastic and normal. In order to clarify the specificities of RAP-5 we applied it to two cell lines: nontumorigenic hamster fibroblasts in which ras expression is barely detectable, and a vigorously tumorigenic line derived from these fibroblasts by insertion of the human mutated Ha-ras oncogene in a high expression vector. Another antibody to p21ras, Y13-259, clearly distinguished between these cell lines both on immunoblots and immunocytochemically, but RAP-5 did not. Rather, it bound to proteins of a variety of molecular weights in both cell lines. The results show that RAP-5 is unlikely to be a useful reagent for detection of ras associated proteins in human tissues.
D000230:Adenocarcinoma / Q000276:immunology; D000236:Adenoma / Q000276:immunology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000276:immunology*; D006224:Cricetinae; D005347:Fibroblasts / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D009857:Oncogenes; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000276:immunology*; D016283:Proto-Oncogene Proteins p21(ras); D012004:Rectal Neoplasms / Q000276:immunology*
D000911:Antibodies, Monoclonal; D011518:Proto-Oncogene Proteins; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)